Dr Lalchandani Labs Ltd.
Snapshot View

24.80 -1.30 ▼-5.0%

03 August 2021, 04:00:00 P.M.
Volume: 4,000

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.lalchandanipathlab.com
Financial Indicators
Market Cap 11.31 Cr.
Earnings per share (EPS) 2.33 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 11.19 Trailing Twelve Months Ending 2021-03
Industry PE 205.26 Trailing Twelve Months Ending 2021-03
Book Value / Share 18.88 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.38 Calculated using Price: 26.10
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.43 Cr. 4,333,068 Shares
FaceValue 10
Company Profile

The Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017.

The Company is formed to set up, engage, collaborate, acquire, purchase, maintain, open collection centres, conduct, manage, administer, own, run laboratories for the purposes of carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.

The company's customers include individual patients, hospitals and other healthcare providers and corporate customers. Diagnostic healthcare testing is an essential element in the delivery of healthcare services, as it provides healthcare service providers with useful information for the diagnosis and treatment of diseases. The Company is NABL Accredited Lab and has established 5 Self-Sufficient Labs and multiple collection centers within Delhi/NCR.

Business area of the Company

They are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, they offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Major Events and Milestones:

  • August, 2017: Incorporation of the Company in the name and style of ‘Dr Lalchandani Labs Limited’ to take over the Existing Partnership Firm.
  • August, 2017: Entered into an Agreement for takeover of the Existing partership Firm named on going concern basis Dr A Lalchandani Pathology Laborataries.
  • January, 2018: Entered in to an Agreement for purchase of acquiring office premises at J-23, Block-J, Lajpat Nagar-III, New Delhi for consideration other than cash from promoter, Arjan Lal  Chandani.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.98%
1 Week
-4.98%
1 Month
+24.00%
3 Month
+1.22%
6 Month
+77.14%
1 Year
+163.83%
2 Year
+74.04%
5 Year
3 years 2018-03 2019-03 2020-03
Return on Equity (%) 8.11 9.85 6.01
Return on Capital Employed (%) 10.06 12.57 9.17
Return on Assets (%) 4.23 6.53 4.30

Balance Sheet View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 3 8 9
Non Curr. Liab. 1 1 2
Curr. Liab. 2 1 2
Minority Int.
Equity & Liab. 6 10 12
Non Curr. Assets 2 4 4
Curr. Assets 4 6 8
Misc. Exp. not W/O 0 0 0
Total Assets 6 10 12

Profit Loss View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 3 5 6
Other Income 0 0
Total Income 3 5 6
Total Expenditure -2 -4 -5
PBIDT 1 1 1
Interest 0 0 0
Depreciation 0 0 0
Taxation 0 0 0
Exceptional Items
PAT 0 1 0

Cash Flow View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 0 0
Cash Fr. Inv. -1 -2 -1
Cash Fr. Finan. 2 4 1
Net Change 1 1 0
Cash & Cash Eqvt 1 2 2

Shareholding Pattern View Details

7 Qtrs 2017-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%)
Promoter 89.80 60.78 60.78 60.78 60.78 60.78 60.78
Public 10.20 39.22 39.22 39.22 39.22 39.22 39.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 12 Jul 2021
Outcome Of Board Meeting
Dr Lalchandani Labs Limited wish to inform you that the Board of Directors of the Company at its meeting held today inter alia has transacted the following:
1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March 2021 along with Auditors Report on Audited Financial Results is also enclosed herewith and

2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March 2021 is enclosed herewith.

Kindly take the same on record and acknowledge.
Mon, 12 Jul 2021
Audited Financial Results For The Half Year And Year Ended March 31 2021
Dr Lalchandani Labs Limited wish to inform you that the Board of Directors of the Company at its meeting held today inter alia has transacted the following:
1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March 2021 along with Auditors Report on Audited Financial Results is also enclosed herewith and

2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March 2021 is enclosed herewith.

Kindly take the same on record and acknowledge.
Tue, 06 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- SWATI PODDAR
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Tue, 27 Jul 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week Low Close Crossing Last Week Low
Opening at High Opening at High
Opening at Low Opening at Low
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 794.85 +2.6%
Divi's Laboratories Ltd. 130,822.92 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,721.20 +0.4%
Cipla Ltd. 74,356.30 927.25 +0.6%
Cadila Healthcare Ltd. 60,574.85 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,317.82 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%